1636
The clinical course suggested that recombinant alpha-2b peginterferon plus ribavirin provoked type 1 diabetes mellitus, therefore, in patients who are candidates for interferon therapy the presence of pancreatic autoantibodies and the fasting plasma glucose level should be investigated before and during treatment.
 ( adverse event: provoked ,  type 1 diabetes mellitus: Effect, recombinant alpha-2b peginterferon plus ribavirin: Treatment, recombinant alpha-2b peginterferon: Treatment.Drug, ribavirin: Treatment.Drug, ribavirin: Combination.Drug, recombinant alpha-2b peginterferon: Combination.Drug) 
Locate the role in the text that participated in the event based on the event type and return it in the event list. 
 Option: Event type: adverse event,potential therapeutic event, Arguments type: Treatment.Disorder,Treatment.Time_elapsed,Treatment.Dosage,Subject.Race,Treatment.Drug,Treatment.Route,Subject.Disorder,Treatment.Freq,Treatment,Effect,Subject.Population,Treatment.Duration,Combination.Drug,Subject,Subject.Age,Subject.Gender. 
Text: {0} 
Answer:
 ( adverse event: provoked ,  type 1 diabetes mellitus: Effect, recombinant alpha-2b peginterferon plus ribavirin: Treatment, recombinant alpha-2b peginterferon: Treatment.Drug, ribavirin: Treatment.Drug, ribavirin: Combination.Drug, recombinant alpha-2b peginterferon: Combination.Drug) 